LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
81.14
+1.05 (+1.31%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close80.09
Open80.27
Bid0.00 x 0
Ask0.00 x 0
Day's Range80.01 - 82.32
52 Week Range73.69 - 89.09
Volume5,379,027
Avg. Volume4,955,906
Market Cap84.551B
Beta0.24
PE Ratio (TTM)N/A
EPS (TTM)-0.19
Earnings DateJul 24, 2018
Forward Dividend & Yield2.25 (2.93%)
Ex-Dividend DateN/A
1y Target Est90.70
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents7 hours ago

    Edited Transcript of LLY earnings conference call or presentation 24-Apr-18 1:00pm GMT

    Q1 2018 Eli Lilly and Co Earnings Call

  • Sanofi’s 1Q18: Revenue Expected to Fall
    Market Realist11 hours ago

    Sanofi’s 1Q18: Revenue Expected to Fall

    As discussed earlier, analysts expect Sanofi’s (SNY) revenue to fall 6.6% to 8.1 billion euros in 1Q18. Let’s look at Sanofi’s segment-wise expectations.

  • GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings
    Market Realist13 hours ago

    GlaxoSmithKline: Operating Revenues Up in 1Q18 Earnings

    GlaxoSmithKline (GSK) beat Wall Street analysts’ estimates for earnings per share (or EPS) and revenues for 1Q18. The above chart compares the quarterly revenues and EPS for GlaxoSmithKline since 1Q17. GlaxoSmithKline reported revenues of 7.2 billion pounds in 1Q18, a 2% decline in revenues, compared to 7.4 billion pounds in 1Q17.

  • Novartis Launches FocalView to Modernize Clinical Trials
    Market Realist13 hours ago

    Novartis Launches FocalView to Modernize Clinical Trials

    Novartis (NVS), a leading pharmaceutical company, includes therapies for retinal disorders, dry eyes, glaucoma, and other eye disorders in its ophthalmology portfolio. On April 25, Novartis launched FocalView, an ophthalmic digital research app created with the help of Apple’s ResearchKit.

  • Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18
    Market Realist13 hours ago

    Amgen’s Earnings Grow 12% Year-Over-Year in 1Q18

    In 1Q18, Amgen (AMGN) generated revenue of $5.6 billion, representing ~2% YoY (year-over-year) growth from its revenue of $5.5 billion in 1Q17. Quarter-over-quarter, its revenue fell ~4%. Amgen’s GAAP (generally accepted accounting principles) operating income and net income rose ~5% and ~12% YoY, respectively, to $2.7 billion and $2.3 billion from $2.6 billion and $2.1 billion.

  • How Analysts Rate Bristol-Myers Squibb in 1Q18
    Market Realist13 hours ago

    How Analysts Rate Bristol-Myers Squibb in 1Q18

    Wall Street analysts estimate Bristol-Myers Squibb’s top line to rise 6.5% to ~$5.2 billion in 1Q18. Also, the earnings per share are expected at $0.85 for 1Q18. The revenue growth is expected to be driven by the prioritized brands including Opdivo, Empliciti, Eliquis, Orencia, Sprycel, and Yervoy, partially offset by lower sales of established brands.

  • A Review of Novo Nordisk’s Modern Insulin
    Market Realist14 hours ago

    A Review of Novo Nordisk’s Modern Insulin

    Novo Nordisk’s (NVO) modern insulins include NovoRapid, Levemir, and NovoMix. In 4Q17, its modern insulins generated revenues of 10.4 billion Danish kroner, which is a ~9% YoY (year-over-year) decline in local currency.

  • Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18
    Market Realist14 hours ago

    Analysts Expect Bristol-Myers Squibb to Post Revenue Growth in 1Q18

    As discussed, Bristol-Myers Squibb (BMY) is expected to report growth of ~6.3% to $5.2 billion in its 1Q18 earnings on April 26. The above graph shows the quarterly revenues of Bristol-Myers Squibb since 1Q17 and analysts’ estimates for 1Q18. Nearly 45% of total revenues for Bristol-Myers Squibb come from international sales, so the company is exposed to currency risk.

  • Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?
    Market Realist15 hours ago

    Novo Nordisk’s New-Generation Insulins: Growth Driver for 2018?

    Novo Nordisk’s (NVO) new-generation insulin portfolio consists of Tresiba, Xultophy, Ryzodeg, and Fiasp.

  • Gilead Sciences has a Strong Oncology Research Program
    Market Realist15 hours ago

    Gilead Sciences has a Strong Oncology Research Program

    Gilead Sciences (GILD) is currently studying a combination of anti-MMP-9 (anti-matrix metalloproteinase-9) antibody andecaliximab with modified FOLFOX 6 in a Phase 3 trial as a therapy for treatment-naïve advanced gastric or GAMMA-1 (gastroesophageal junction adenocarcinoma) patients. The company also expects to conclude its Phase 2 trial comparing an andecaliximab-nivolumab combination with a nivolumab monotherapy in gastric cancer in 2018. If these trials prove successful, Gilead Sciences could emerge as major competition for other gastric cancer therapy players such as Eli Lilly (LLY) and Roche (RHHBY).

  • Why Incyte Stock Fell ~9% on April 24
    Market Realist16 hours ago

    Why Incyte Stock Fell ~9% on April 24

    On April 24, Incyte (INCY) saw a steep decline in its stock price. It registered a decline of ~5% during pre-market trading. The stock price decline was triggered by the news regarding Incyte-Eli Lily (LLY) drug Baricitinib, which is under FDA (U.S. Food and Drug Administration) review.

  • Novo Nordisk’s Xultophy Expected to See High Growth in 2018
    Market Realist17 hours ago

    Novo Nordisk’s Xultophy Expected to See High Growth in 2018

    In fiscal 2017, Novo Nordisk’s (NVO) Xultophy generated revenues of 729 million Danish kroner compared to 207 million Danish kroner in 2016. That’s a ~255% YoY (year-over-year) growth in local currency.

  • How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18
    Market Realist17 hours ago

    How Johnson & Johnson’s Medical Devices Segment Performed in 1Q18

    Johnson & Johnson’s (JNJ) medical devices business includes cardiovascular care products, orthopedics products, surgery products, vision care products, and diabetes products. The medical devices business reported 7.5% growth in revenues to $6.8 billion during 1Q18 as compared to revenues of $6.3 billion during 1Q17. The growth includes 3.2% growth in revenues at constant exchange rates and a 4.3% increase due to the positive impact of foreign exchange.

  • Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease
    PR Newswire17 hours ago

    Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease

    - Collaboration between China's National Center for Cardiovascular Diseases and Lilly aims to improve care for people living with Type 2 diabetes in China - The Lilly and NCCD collaboration will address ...

  • Is Eli Lilly and Company a Buy?
    Motley Fool18 hours ago

    Is Eli Lilly and Company a Buy?

    Lilly's first-quarter results looked good. Is it time to buy the big pharma stock?

  • Eli Lilly Lures Bain, Advent on Animal Health Sale
    Bloombergyesterday

    Eli Lilly Lures Bain, Advent on Animal Health Sale

    Eli Lilly & Co. has attracted interest from private equity firms including Bain Capital and Advent International Corp. for its animal-health business, as the pharmaceutical giant considers options for ...

  • Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018
    Market Realistyesterday

    Tresiba Could Significantly Drive Novo Nordisk’s Revenue in 2018

    In 4Q17, Novo Nordisk’s (NVO) Tresiba generated revenues of 1.9 billion Danish kroner, which is a ~48% YoY (year-over-year) growth in local currency.

  • TheStreet.comyesterday

    Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

    Stocks finished sharply lower Tuesday, as corporate earnings disappoint investors.

  • Eli Lilly Tops On Diabetes, Chemo Strength But A Key Drug Lagged
    Investor's Business Dailyyesterday

    Eli Lilly Tops On Diabetes, Chemo Strength But A Key Drug Lagged

    Eli Lilly topped the Street's first-quarter estimates Tuesday on unexpected strength from two diabetes drugs and the early impact of a chemotherapy tie with Dow Jones' component Merck.

  • Ozempic Could Be Potential Driver for Novo Nordisk in 2018
    Market Realistyesterday

    Ozempic Could Be Potential Driver for Novo Nordisk in 2018

    In December 2017, the FDA approved Novo Nordisk’s (NVO) Ozempic as an add-on to diet and exercise for the management of blood sugar levels in adult individuals with Type 2 diabetes.

  • InvestorPlaceyesterday

    Eli Lilly And Co Produced a Monstrous Q1 Beat, But Is It Enough?

    It’s a busy week for pharmaceutical companies, with Eli Lilly And Co (NYSE:LLY), Biogen Inc (NASDAQ:BIIB), and Amgen, Inc. (NASDAQ:AMGN) having released their earnings report today. For Eli Lilly stock, investors sought a definitive sign where the renowned firm was headed. Since early summer of 2015, Eli Lilly stock gyrated wildly between bullish and bearish phases, only to come out dead even.

  • Reutersyesterday

    Express Scripts targets Amgen, Lilly migraine drugs in pricing shift

    The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc (AMGN.O), Eli Lilly and Co (LLY.N) and other makers of new migraine medicines to try and fix it. Express Scripts (ESRX.O) told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.

  • CNBCyesterday

    Why the market is blowing off what has been a really good earnings season

    Corporate America is well on its way to what could be a record-breaking profit season, and investors don't really care. Despite earnings growth of more than 18 percent, the market is little changed since ...

  • TheStreet.comyesterday

    Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

    rheumatoid arthritis drug baricitinib, Eli Lilly chairman and CEO David Ricks on an earnings call Tuesday expressed confidence in the benefit-risk profile of both doses of the treatment. The advisory panel recommended that the FDA approve the 2-mg dose of baricitinib, but not the 4-mg dose for the proposed indication based on the adequacy of the safety and benefit-risk profiles. "While we are pleased that the FDA's arthritis advisory committee supported the efficacy of both 2 mg and 4 mg of baricitinib in RA and 2 mg overall, we are disappointed that the committee did not recommend approval of the 4-mg dose," Ricks said.

  • Is There An Opportunity With Eli Lilly and Company’s (NYSE:LLY) 26% Undervaluation?
    Simply Wall St.2 days ago

    Is There An Opportunity With Eli Lilly and Company’s (NYSE:LLY) 26% Undervaluation?

    Does the share price for Eli Lilly and Company (NYSE:LLY) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value using the discounted cash flow (DCF) method. AnyoneRead More...